Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydrocortisone modified-release
- Development stage
- Phase 3
- Lead developer
- Neurocrine Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Chronocort is a modified-release preparation of hydrocortisone specifically designed to mimic the circadian rhythm of cortisol when given in a twice-daily regimen. It uses multiparticulate technology with an enteric coat that has a pH trigger of 6.8, allowing small bowel dissolution. This formulation enables a more physiologic cortisol replacement therapy for patients with congenital adrenal hyperplasia (CAH) and potentially adrenal insufficiency.
- Brand names
- Efmody
- Other names
- hydrocortisone modified-release hard capsules
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on hydrocortisone modified-release.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydrocortisone modified-release.